Capsule independent uptake of the fungal pathogen cryptococcus neoformans into brain microvascular endothelial cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Sabiiti, Wilber ^a   May, Robin C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRUCTURES; FUNGUS CAPSULE; HUMAN; HUMAN CELL; INTERNALIZATION; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; OPSONIZATION; SIGNAL TRANSDUCTION; SURVIVAL; YEAST CELL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CELL LINE; CRYPTOCOCCUS NEOFORMANS; ENDOCYTOSIS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MICE;

FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 84859815859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035455     Document Type: Article

References (43)

1. Lin X, (2009) Cryptococcus neoformans: Morphogenesis, infection, and evolution. Infect Genet Evol 9 (4): 401-416.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23 (4): 525-530.
3. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, et al. (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on vancouver island (british columbia, canada). Proc Natl Acad Sci U S A 101 (49): 17258-17263.
4. Byrnes EJ 3rd, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, et al. (2009) Molecular evidence that the range of the Vancouver island outbreak of cryptococcus gattii infection has expanded into the pacific northwest in the united states. J Infect Dis 199 (7): 1081-1086.
5. Byrnes EJ 3rd, Li W, Lewit Y, Ma H, Voelz K, et al. (2010) Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest united states. PLoS Pathog 6 (4): e1000850.
6. Byrnes EJ, Heitman J, (2009) Cryptococcus gattii outbreak expands into the northwestern united states with fatal consequences. F1000 Biol Rep 1: 62.
7. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, et al. (2009) Spread of Cryptococcus gattii into pacific northwest region of the united states. Emerging Infect Dis 15 (8): 1185-1191.
8. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, et al. (2010) Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 12 (3): 220-229.
9. Mitchell TG, Perfect JR, (1995) Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8 (4): 515-548.
10. Huffnagle GB, McNeil LK, (1999) Dissemination of C. neoformans to the central nervous system: Role of chemokines, Th1 immunity and leukocyte recruitment. J Neurovirol 5 (1): 76-81.
11. Casadevall A, Perfect JR, eds. (1998) Cryptococcus neoformans. Washington, DC American Society for Microbiology.
12. Lortholary O, (2007) Management of cryptococcal meningitis in AIDS: The need for specific studies in developing countries. Clin Infect Dis 45 (1): 81-83.
13. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, et al. (2010) Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 202 (6): 962-970.
14. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, et al. (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: A randomized trial in malawi. Clin Infect Dis 50 (3): 338-344.
15. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, et al. (2008) Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 46 (11): 1694-1701.
16. Bicanic T, Harrison TS, (2005) Cryptococcal meningitis. Br Med Bull 72: 99-118.
17. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, et al. (2001) Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in zambian AIDS patients treated under local conditions. Postgrad Med J pp. 769-73.
18. Kim KS, (2008) Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol 6 (8): 625-634.
19. Brown RC, Morris AP, O'Neil RG, (2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130 (1): 17-30.
20. Correale J, Villa A, (2009) Cellular elements of the blood-brain barrier. Neurochem Res.
21. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, et al. (2009) Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun 77 (1): 120-127.
22. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, et al. (2004) Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 72 (9): 4985-4995.
23. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, et al. (2004) Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 72 (9): 4985-4995.
24. Eisenman HC, Casadevall A, McClelland EE, (2007) New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep 9 (6): 457-464.
25. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, et al. (2011) Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem 286 (40): 34761-34769.
26. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A, Washington, eds. (2010) Cryptococcus: From human pathogen to model yeast. DC ASM Press.
27. Fries BC, Taborda CP, Serfass E, Casadevall A, (2001) Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest 108 (11): 1639-1648.
28. Chen SH, Stins MF, Huang SH, Chen YH, Kwon-Chung K, et al. (2003) Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol 52: 961-970.
29. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, et al. (2005) Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol 166 (2): 421-432.
30. Guerrero A, Jain N, Goldman DL, Fries BC, (2006) Phenotypic switching in Cryptococcus neoformans. Microbiology 152: 3-9.
31. Jain N, Guerrero A, Fries BC, (2006) Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans. FEMS Yeast Res 6 (4): 480-488.
32. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, et al. (2010) Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 120 (5): 1683-1693.
33. Jong AY, Stins MF, Huang SH, Chen SH, Kim KS, (2001) Traversal of Candida albicans across human blood-brain barrier in vitro. Infect Immun 69 (7): 4536-4544.
34. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, et al. (2001) Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107 (5): E66.
35. Mukherjee S, Lee SC, Casadevall A, (1995) Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 63 (2): 573-579.
36. Vecchiarelli A, Pietrella D, Bistoni F, Kozel TR, Casadevall A, (2002) Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunology 106 (2): 267-272.
37. Bolanos B, Mitchell TG, (1989) Phagocytosis and killing of Cryptococcus neoformans by rat alveolar macrophages in the absence of serum. J Leukoc Biol 46 (6): 521-528.
38. De Jesus M, Chow SK, Cordero RJ, Frases S, Casadevall A, (2010) Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryot Cell 9 (7): 1018-1028.
39. Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, et al. (2004) Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun 72 (4): 2229-2239.
40. Syme RM, Bruno TF, Kozel TR, Mody CH, (1999) The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun 67 (9): 4620-4627.
41. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, et al. (2008) Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol 10 (10): 2043-2057.
42. Ibrahim AS, Filler SG, Alcouloumre MS, Kozel TR, Edwards JE, et al. (1995) Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: Role of the capsule. Infect Immun 63 (11): 4368-4374.
43. Ma H, May RC, (2009) Virulence in Cryptococcus species. Adv Appl Microbiol 67: 131-190.